Skip to main content
SpringerLink
Log in

Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer

  • Chapter
  • First Online:
Urologic Oncology

  • 787 Accesses

Abstract

Selective bladder preservation (SBP) has emerged as an excellent treatment option for patients with muscle-invasive bladder cancer (MIBC) deemed eligible for consideration based on certain selection criteria. This chapter describes the clinical entity of MIBC, discusses the selection criteria utilized for evaluating candidacy for SBP, and addresses a multitude of bladder-sparing approaches that have been utilized both historically and in current clinical practice. An emphasis is placed on discussion of trimodality therapy (TMT) incorporating maximal transurethral resection of bladder tumor (TURBT) and concurrent chemoradiotherapy +/− immunotherapy. Discussion of SBP includes presentation of general treatment paradigms, a review of existing literature describing oncologic outcomes, discussion of quality of life considerations, and description of treatment planning techniques for high-quality radiotherapy (RT) delivery. Ongoing randomized clinical trials (RCTs) of interest will be underscored throughout as they pertain to each aspect of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel, Switzerland). 2020;8(1):15. https://doi.org/10.3390/medsci8010015.

    Article  CAS  Google Scholar 

  2. Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019;74(1):112–34. https://doi.org/10.1111/his.13734.

    Article  PubMed  Google Scholar 

  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  4. Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12(1):97–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhu C-Z, Ting H-N, Ng K-H, Ong T-A. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019;10(17):4038–44. https://doi.org/10.7150/jca.28989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Galgano SJ, Porter KK, Burgan C, Rais-Bahrami S. The role of imaging in bladder cancer diagnosis and staging. Diagnostics (Basel, Switzerland). 2020;10(9). https://doi.org/10.3390/diagnostics10090703.

  7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(3):666–75. https://doi.org/10.1200/JCO.2001.19.3.666.

    Article  CAS  Google Scholar 

  8. Muilwijk T, Akand M, Gevaert T, Joniau S. No survival difference between super extended and standard lymph node dissection at radical cystectomy: what can we learn from the first prospective randomized phase III trial? Transl Androl Urol. 2019;8(Suppl 1):S112–5. https://doi.org/10.21037/tau.2018.12.09.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gschwend JE, Heck MM, Lehmann J, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol. 2019;75(4):604–11. https://doi.org/10.1016/j.eururo.2018.09.047.

    Article  PubMed  Google Scholar 

  10. Siddiqui KM, Izawa JI. Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy. World J Urol. 2016;34(1):19–24. https://doi.org/10.1007/s00345-015-1706-1.

    Article  PubMed  Google Scholar 

  11. Monn MF, Kaimakliotis HZ, Cary KC, et al. Short-term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy. Urol Oncol. 2014;32(8):1151–7. https://doi.org/10.1016/j.urolonc.2014.04.009.

    Article  PubMed  Google Scholar 

  12. Lukka H. In favour of bladder preservation using combined modality treatment. Can Urol Assoc J = J l’Association des Urol du Canada. 2009;3(5):412–5. https://doi.org/10.5489/cuaj.1157.

    Article  Google Scholar 

  13. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165(4):1111–6.

    Article  CAS  PubMed  Google Scholar 

  14. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. https://doi.org/10.1056/NEJMoa022148.

    Article  CAS  PubMed  Google Scholar 

  15. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–6. https://doi.org/10.1016/j.eururo.2005.04.006.

  16. Eisenberg MS, Thompson RH, Frank I, et al. Long-term renal function outcomes after radical cystectomy. J Urol. 2014;191(3):619–25. https://doi.org/10.1016/j.juro.2013.09.011.

    Article  PubMed  Google Scholar 

  17. Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23(3):511–7. https://doi.org/10.1016/0360-3016(92)90005-3.

    Article  CAS  PubMed  Google Scholar 

  18. Zaghloul MS, Christodouleas JP, Smith A, et al. Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial. JAMA Surg. 2018;153(1):e174591. https://doi.org/10.1001/jamasurg.2017.4591.

    Article  PubMed  Google Scholar 

  19. Christodouleas JP, Hwang W-T, Baumann BC. Adjuvant radiation for locally advanced bladder cancer? A question worth asking. Int J Radiat Oncol Biol Phys. 2016;94(5):1040–2. https://doi.org/10.1016/j.ijrobp.2016.01.015.

    Article  PubMed  Google Scholar 

  20. Baumann BC, Bosch WR, Bahl A, et al. Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy. Int J Radiat Oncol Biol Phys. 2016;96(1):78–86. https://doi.org/10.1016/j.ijrobp.2016.04.032.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Solanki AA, Martin B, Korpics M, Small C, Harkenrider MM, Mitin T. Adjuvant radiotherapy use by US radiation oncologists after radical cystectomy for muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol). 2017;29(7):429–35. https://doi.org/10.1016/j.clon.2017.02.005.

    Article  CAS  Google Scholar 

  22. Fischer-Valuck BW, Michalski JM, Mitra N, et al. Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Med. 2019;8(8):3698–709. https://doi.org/10.1002/cam4.2102.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Soulié M, Straub M, Gamé X, et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 2002;167(3):1325–8.

    Article  PubMed  Google Scholar 

  24. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296–300. https://doi.org/10.1016/j.juro.2010.06.007.

    Article  CAS  PubMed  Google Scholar 

  25. Novotny V, Hakenberg OW, Wiessner D, et al. Perioperative complications of radical cystectomy in a contemporary series. Eur Urol. 2007;51(2):392–7. https://doi.org/10.1016/j.eururo.2006.06.014.

    Article  Google Scholar 

  26. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55(1):177–85. https://doi.org/10.1016/j.eururo.2008.07.018.

    Article  PubMed  Google Scholar 

  27. Novara G, Catto JWF, Wilson T, et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol. 2015;67(3):376–401. https://doi.org/10.1016/j.eururo.2014.12.007.

    Article  PubMed  Google Scholar 

  28. Reisinger SA, Mohiuddin M, Mulholland SG. Combined pre- and postoperative adjuvant radiation therapy for bladder cancer--a ten year experience. Int J Radiat Oncol Biol Phys. 1992;24(3):463–8. https://doi.org/10.1016/0360-3016(92)91060-z.

    Article  CAS  PubMed  Google Scholar 

  29. Santos F, Zakaria AS, Kassouf W, Tanguay S, Aprikian A. High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec. World J Urol. 2015;33(9):1323–30. https://doi.org/10.1007/s00345-014-1457-4.

    Article  PubMed  Google Scholar 

  30. Bajaj A, Martin B, Bhasin R, et al. The impact of academic facility type and case volume on survival in patients undergoing curative radiation therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2018;100(4):851–7. https://doi.org/10.1016/j.ijrobp.2017.11.040.

    Article  PubMed  Google Scholar 

  31. Mirza A, Choudhury A. Bladder preservation for muscle invasive bladder cancer. Bladder cancer (Amsterdam, Netherlands). 2016;2(2):151–63. https://doi.org/10.3233/BLC-150025.

    Article  PubMed Central  Google Scholar 

  32. Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol. 2020;46(2):169–84. https://doi.org/10.1590/S1677-5538.IBJU.2020.99.01.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Winquist E, Booth CM. Trimodality therapy for muscle-invasive bladder cancer: concurrent chemotherapy is not enough. J Clin Oncol. 2020;38(24):2709–11. https://doi.org/10.1200/JCO.19.02959.

    Article  PubMed  Google Scholar 

  34. Ritch CR, Balise R, Prakash NS, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int. 2018;121(5):745–51. https://doi.org/10.1111/bju.14109.

    Article  PubMed  Google Scholar 

  35. Hollenbeck BK, Miller DC, Dunn RL, Montie JE, Wei JT. The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol. 2005;23(2):77–81. https://doi.org/10.1016/j.urolonc.2004.08.012.

    Article  PubMed  Google Scholar 

  36. van Dijk PR, Ploeg M, Aben KKH, et al. Downstaging of TURBT-based muscle-invasive bladder cancer by radical cystectomy predicts better survival. ISRN Urol. 2011;2011:458930. https://doi.org/10.5402/2011/458930.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Marchioni M, Primiceri G, Delli Pizzi A, et al. Could bladder multiparametric MRI be introduced in routine clinical practice? Role of the new VI-RADS score: results from a prospective study. Clin Genitourin Cancer. 2020;18(5):409–415.e1. https://doi.org/10.1016/j.clgc.2020.03.002.

    Article  PubMed  Google Scholar 

  38. James ND, Pirrie S, Liu W, et al. Replacing TURBT with mpMRI for staging MIBC: pilot data from the BladderPath study. J Clin Oncol. 2020;38(6_suppl):446. https://doi.org/10.1200/JCO.2020.38.6_suppl.446.

    Article  Google Scholar 

  39. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(20):2299–305. https://doi.org/10.1200/JCO.2016.69.2327.

    Article  Google Scholar 

  40. Zhong J, Switchenko J, Jegadeesh NK, et al. Comparison of outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preservation. Am J Clin Oncol. 2019;42(1):36–41. https://doi.org/10.1097/COC.0000000000000471.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Vashistha V, Wang H, Mazzone A, et al. Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–20. https://doi.org/10.1016/j.ijrobp.2016.11.056.

    Article  PubMed  Google Scholar 

  42. Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):639–50. https://doi.org/10.1111/bju.13900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol. 1987;138(5):1162–3. https://doi.org/10.1016/S0022-5347(17)43535-X.

    Article  CAS  PubMed  Google Scholar 

  44. Henry K, Miller J, Mori M, Loening S, Fallon B. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol. 1988;140(5):964–7. https://doi.org/10.1016/s0022-5347(17)41899-4.

    Article  CAS  PubMed  Google Scholar 

  45. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19(1):89–93. https://doi.org/10.1200/JCO.2001.19.1.89.

    Article  CAS  PubMed  Google Scholar 

  46. Barnes RW, Dick AL, Hadley HL, Johnston OL. Survival following transurethral resection of bladder carcinoma. Cancer Res. 1977;37(8 Pt 2):2895–7.

    CAS  PubMed  Google Scholar 

  47. Milner WA. The role of conservative surgery in the treatment of bladder tumours. Br J Urol. 1954;26(4):375–86. https://doi.org/10.1111/j.1464-410x.1954.tb04920.x.

    Article  CAS  PubMed  Google Scholar 

  48. Nerli RB, Reddy M, Koura AC, Prabha V, Ravish IR, Amarkhed S. Cystoscopy-assisted laparoscopic partial cystectomy. J Endourol. 2008;22(1):83–6. https://doi.org/10.1089/end.2007.0105.

    Article  PubMed  Google Scholar 

  49. Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80–108. https://doi.org/10.1016/j.currproblcancer.2014.06.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ma B, Li H, Zhang C, et al. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2013;39(10):1150–6. https://doi.org/10.1016/j.ejso.2013.04.006.

    Article  CAS  Google Scholar 

  51. Kassouf W, Swanson D, Kamat AM, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006;175(6):2058–62. https://doi.org/10.1016/S0022-5347(06)00322-3.

    Article  PubMed  Google Scholar 

  52. Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004;172(3):878–81. https://doi.org/10.1097/01.ju.0000135530.59860.7d.

    Article  PubMed  Google Scholar 

  53. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RLJ. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. 2008;72(3):613–6. https://doi.org/10.1016/j.urology.2008.04.052.

    Article  PubMed  Google Scholar 

  54. Mistretta FA, Cyr S-J, Luzzago S, et al. Partial cystectomy with pelvic lymph node dissection for patients with nonmetastatic stage pT2-T3 urothelial carcinoma of urinary bladder: temporal trends and survival outcomes. Clin Genitourin Cancer. 2020;18(2):129–137.e3. https://doi.org/10.1016/j.clgc.2019.09.008.

    Article  PubMed  Google Scholar 

  55. Fahmy N, Aprikian A, Tanguay S, et al. Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol. 2010;28(4):419–23. https://doi.org/10.1007/s00345-009-0478-x.

    Article  PubMed  Google Scholar 

  56. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1986;7(4):299–310. https://doi.org/10.1016/s0167-8140(86)80059-7.

    Article  CAS  Google Scholar 

  57. Quilty PM, Duncan W. The influence of hemoglobin level on the regression and long term local control of transitional cell carcinoma of the bladder following photon irradiation. Int J Radiat Oncol Biol Phys. 1986;12(10):1735–42. https://doi.org/10.1016/0360-3016(86)90313-5.

    Article  CAS  PubMed  Google Scholar 

  58. Davidson SE, Symonds RP, Snee MP, Upadhyay S, Habeshaw T, Robertson AG. Assessment of factors influencing the outcome of radiotherapy for bladder cancer. Br J Urol. 1990;66(3):288–93. https://doi.org/10.1111/j.1464-410x.1990.tb14929.x.

    Article  CAS  PubMed  Google Scholar 

  59. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30(2):267–77. https://doi.org/10.1016/0360-3016(94)90004-3.

    Article  CAS  PubMed  Google Scholar 

  60. Sauer R, Birkenhake S, Kühn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):121–7. https://doi.org/10.1016/s0360-3016(97)00579-8.

    Article  CAS  PubMed  Google Scholar 

  61. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. https://doi.org/10.1056/NEJMoa1106106.

    Article  CAS  PubMed  Google Scholar 

  62. Barringer BS. Radium treatment of cancer of the bladder. Ann Surg. 1935;101(6):1425–8. https://doi.org/10.1097/00000658-193506000-00015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Barringer BS. Twenty-five years of radon treatment of cancer of the bladder. JAMA. 1947;135(10):616–8.

    Article  CAS  Google Scholar 

  64. Lenz M, Cahill GF. The treatment of cancer of the bladder by radium needles. Am J Roentgenol Radium Ther. 1947;58(4):486–92.

    CAS  PubMed  Google Scholar 

  65. Wijnmaalen A, Helle PA, Koper PC, et al. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192. Int J Radiat Oncol Biol Phys. 1997;39(5):1043–52. https://doi.org/10.1016/s0360-3016(97)00375-1.

    Article  CAS  PubMed  Google Scholar 

  66. Rozan R, Albuisson E, Donnarieix D, et al. Interstitial iridium-192 for bladder cancer (A multicentric survey: 205 patients). Int J Radiat Oncol. 1992;24(3):469–77. https://doi.org/10.1016/0360-3016(92)91061-Q.

    Article  CAS  Google Scholar 

  67. Pernot M, Hubert J, Guillemin F, et al. Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192). Radiother Oncol J Eur Soc Ther Radiol Oncol. 1996;38(2):115–20. https://doi.org/10.1016/0167-8140(96)82354-1.

    Article  CAS  Google Scholar 

  68. Bos MK, Marmolejo RO, Rasch CRN, Pieters BR. Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review. J Contemp Brachytherapy. 2014;6(2):191–9. https://doi.org/10.5114/jcb.2014.43777.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Sternberg CN, Pansadoro V, Calabrò F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97(7):1644–52. https://doi.org/10.1002/cncr.11232.

    Article  PubMed  Google Scholar 

  70. Herr HW, Scher HI. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(5):975–80. https://doi.org/10.1200/JCO.1994.12.5.975.

    Article  CAS  Google Scholar 

  71. Bazzi WM, Kopp RP, Donahue TF, et al. Partial cystectomy after neoadjuvant chemotherapy: Memorial Sloan Kettering Cancer Center contemporary experience. Int Sch Res Not. 2014;2014:702653. https://doi.org/10.1155/2014/702653.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Thomas R, Hall R. Radical transurethral resection and chemotherapy in. BJU Int. 1999;83(4):432–7. https://doi.org/10.1046/j.1464-410x.1999.00970.x.

    Article  CAS  PubMed  Google Scholar 

  73. Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009;55(4):911–9. https://doi.org/10.1016/j.eururo.2008.08.027.

    Article  PubMed  Google Scholar 

  74. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase. Lancet Oncol. 2013;14(9):863–72. https://doi.org/10.1016/S1470-2045(13)70255-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Coen JJ, Zhang P, Saylor PJ, et al. Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712-a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(1):44–51. https://doi.org/10.1200/JCO.18.00537.

    Article  CAS  Google Scholar 

  76. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(14):3061–71. https://doi.org/10.1200/JCO.2002.11.027.

    Article  Google Scholar 

  77. Perdonà S, Autorino R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer. 2008;112(1):75–83. https://doi.org/10.1002/cncr.23137.

    Article  PubMed  Google Scholar 

  78. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11. https://doi.org/10.1016/j.eururo.2011.11.010.

    Article  PubMed  Google Scholar 

  79. Fung CY, Shipley WU, Young RH, et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9(9):1533–42. https://doi.org/10.1200/JCO.1991.9.9.1533.

    Article  CAS  Google Scholar 

  80. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(11):3576–83. https://doi.org/10.1200/JCO.1998.16.11.3576.

    Article  CAS  Google Scholar 

  81. Krasnow RE, Drumm M, Roberts HJ, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol. 2017;72(1):54–60. https://doi.org/10.1016/j.eururo.2016.12.002.

    Article  PubMed  Google Scholar 

  82. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(11):2150–7. https://doi.org/10.1200/JCO.1993.11.11.2150.

    Article  CAS  Google Scholar 

  83. Sauer R, Dunst J, Altendorf-Hofmann A, Fischer H, Bornhof C, Schrott KM. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys. 1990;19(3):687–91. https://doi.org/10.1016/0360-3016(90)90497-8.

    Article  CAS  PubMed  Google Scholar 

  84. Shipley WU, Prout GRJ, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258(7):931–5.

    Article  CAS  PubMed  Google Scholar 

  85. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993;329(19):1377–82. https://doi.org/10.1056/NEJM199311043291903.

    Article  CAS  PubMed  Google Scholar 

  86. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25(5):783–90. https://doi.org/10.1016/0360-3016(93)90306-g.

    Article  CAS  PubMed  Google Scholar 

  87. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(1):119–26. https://doi.org/10.1200/JCO.1996.14.1.119.

    Article  CAS  Google Scholar 

  88. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471–6. https://doi.org/10.1634/theoncologist.5-6-471.

    Article  CAS  PubMed  Google Scholar 

  89. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665–72. https://doi.org/10.1016/s0360-3016(03)00718-1.

    Article  PubMed  Google Scholar 

  90. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7. https://doi.org/10.1016/j.urology.2008.09.036.

    Article  PubMed  Google Scholar 

  91. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3801–9. https://doi.org/10.1200/JCO.2014.57.5548.

    Article  Google Scholar 

  92. Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74(2):511–7. https://doi.org/10.1016/j.ijrobp.2008.08.021.

    Article  CAS  PubMed  Google Scholar 

  93. Hall E, Hussain SA, Porta N, et al. BC2001 long-term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer. J Clin Oncol. 2017;35(6_suppl):280. https://doi.org/10.1200/JCO.2017.35.6_suppl.280.

    Article  Google Scholar 

  94. Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155(6):1903–6.

    Article  PubMed  Google Scholar 

  95. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol. 1995;153(3 Pt 2):964–73.

    PubMed  Google Scholar 

  96. Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018;4(11):1535–42. https://doi.org/10.1001/jamaoncol.2018.3542.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67(6):608–15. https://doi.org/10.1111/j.1464-410x.1991.tb15225.x.

    Article  CAS  PubMed  Google Scholar 

  98. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet (London, England). 1999;354(9178):533–40.

    Google Scholar 

  99. Hussain SA, Porta N, Hall E, et al. Outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by (chemo)radiotherapy in the BC2001 trial. Eur Urol. 2021;79(2):307–15. https://doi.org/10.1016/j.eururo.2020.11.036.

    Article  CAS  PubMed  Google Scholar 

  100. Horwich A, Dearnaley D, Huddart R, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2005;75(1):34–43. https://doi.org/10.1016/j.radonc.2004.11.003.

    Article  Google Scholar 

  101. Näslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol. 1994;33(4):397–402. https://doi.org/10.3109/02841869409098435.

    Article  PubMed  Google Scholar 

  102. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997;37(2):259–67. https://doi.org/10.1016/s0360-3016(96)00511-1.

    Article  CAS  PubMed  Google Scholar 

  103. Pos FJ, Hart G, Schneider C, Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys. 2006;64(4):1168–73. https://doi.org/10.1016/j.ijrobp.2005.09.023.

    Article  PubMed  Google Scholar 

  104. Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22(2):246–55. https://doi.org/10.1016/S1470-2045(20)30607-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6(1):10–21. https://doi.org/10.1053/SRAO0060010.

    Article  CAS  PubMed  Google Scholar 

  106. Hoskin PJ, Saunders MI, Phillips H, et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer. 1997;76(2):260–3. https://doi.org/10.1038/bjc.1997.372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(33):4912–8. https://doi.org/10.1200/JCO.2010.28.4950.

    Article  Google Scholar 

  108. Song YP, Mistry H, Choudhury A, Hoskin P. Long-term outcomes of hypoxia modification in bladder preservation: update from BCON trial. J Clin Oncol. 2019;37(7_suppl):356. https://doi.org/10.1200/JCO.2019.37.7_suppl.356.

    Article  Google Scholar 

  109. Eustace A, Irlam JJ, Taylor J, et al. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108(1):40–7. https://doi.org/10.1016/j.radonc.2013.05.017.

    Article  Google Scholar 

  110. Yang L, Taylor J, Eustace A, et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin cancer Res an Off J Am Assoc Cancer Res. 2017;23(16):4761–8. https://doi.org/10.1158/1078-0432.CCR-17-0038.

    Article  CAS  Google Scholar 

  111. Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Research. 2018;7. https://doi.org/10.12688/f1000research.14903.1.

  112. Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–556.e25. https://doi.org/10.1016/j.cell.2017.09.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. https://doi.org/10.1016/j.ccr.2014.01.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Mitra AP. Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol. 2016;8(3):215–33. https://doi.org/10.1177/1756287216638981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Choudhury A, Nelson LD, Teo MTW, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010;70(18):7017–26. https://doi.org/10.1158/0008-5472.CAN-10-1202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33. https://doi.org/10.1016/j.eururo.2019.09.006.

    Article  PubMed  Google Scholar 

  117. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2.

    Article  CAS  PubMed  Google Scholar 

  118. Grivas P. DNA damage response gene alterations in urothelial cancer: ready for practice? Clin Cancer Res an Off J Am Assoc Cancer Res. 2019;25(3):907–9. https://doi.org/10.1158/1078-0432.CCR-18-2512.

    Article  CAS  Google Scholar 

  119. Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–23. https://doi.org/10.3322/caac.21631.

    Article  PubMed  Google Scholar 

  120. Cuellar MA, Medina A, Girones R, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: a SOGUG study. J Clin Oncol. 2020;38(15_suppl):TPS5097-TPS5097. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS5097.

    Article  Google Scholar 

  121. Balar AV, James ND, Shariat SF, et al. Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992. J Clin Oncol. 2020;38(15_suppl):TPS5093-TPS5093. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS5093.

    Article  Google Scholar 

  122. Jiang DM, Chung P, Kulkarni GS, Sridhar SS. Trimodality therapy for muscle-invasive bladder cancer: recent advances and unanswered questions. Curr Oncol Rep. 2020;22(2):14. https://doi.org/10.1007/s11912-020-0880-5.

    Article  PubMed  Google Scholar 

  123. Singh P, Tangen C, Efstathiou JA, et al. INTACT: phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. J Clin Oncol. 2020;38(6_suppl):TPS586-TPS586. https://doi.org/10.1200/JCO.2020.38.6_suppl.TPS586.

    Article  Google Scholar 

  124. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1991;21(3):163–70. https://doi.org/10.1016/0167-8140(91)90033-d.

    Article  CAS  Google Scholar 

  125. Moonen L, vd Voet H, de Nijs R, Horenblas S, Hart AA, Bartelink H. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys. 1998;42(3):525–30. https://doi.org/10.1016/s0360-3016(98)00263-6.

    Article  CAS  PubMed  Google Scholar 

  126. Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(3):329–54. https://doi.org/10.6004/jnccn.2020.0011.

    Article  PubMed  Google Scholar 

  127. Witjes JA, Bruins M, Cathomas R, et al. European Association of Urology guidelines. 2020 Edition. In: Vol presented. European Association of Urology Guidelines Office. 2020. http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.

  128. Kassam SN, Aziz Z, Hung LS, Sridhar SS. A case of isolated rectal recurrence of muscle invasive bladder cancer. Can Urol Assoc J = J l’Association des Urol du Canada. 2013;7(5–6):E376–80. https://doi.org/10.5489/cuaj.1223.

    Article  Google Scholar 

  129. Reshko LB, Richardson MK, Spencer K, Kersh CR. Stereotactic body radiation therapy (SBRT) in pelvic lymph node oligometastases. Cancer Invest. 2020;38(10):599–607. https://doi.org/10.1080/07357907.2020.1801713.

    Article  PubMed  Google Scholar 

  130. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int. 1999;62(2):69–75. https://doi.org/10.1159/000030361.

    Article  CAS  PubMed  Google Scholar 

  131. Joshi M, Kim S, Solanki AA, et al. EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration. J Clin Oncol. 2021;39(6):TPS500

    Google Scholar 

  132. Haque W, Verma V, Butler EB, Teh BS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer (Amsterdam, Netherlands). 2017;3(4):283–91. https://doi.org/10.3233/BLC-170137.

    Article  Google Scholar 

  133. Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–57. https://doi.org/10.1111/bju.14047.

    Article  PubMed  Google Scholar 

  134. Shih C, Porter MP. Health-related quality of life after cystectomy and urinary diversion for bladder cancer. Meng M V, ed. Adv Urol. 2011;2011:715892. https://doi.org/10.1155/2011/715892.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Modh RA, Mulhall JP, Gilbert SM. Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol. 2014;11(8):445–53. https://doi.org/10.1038/nrurol.2014.151.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007;109(9):1756–62. https://doi.org/10.1002/cncr.22556.

    Article  PubMed  Google Scholar 

  137. Mak KS, Smith AB, Eidelman A, et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;96(5):1028–36. https://doi.org/10.1016/j.ijrobp.2016.08.023.

    Article  PubMed  Google Scholar 

  138. Henningsohn L, Wijkström H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2002;62(2):215–25. https://doi.org/10.1016/s0167-8140(01)00455-8.

    Article  Google Scholar 

  139. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170(5):1772–6. https://doi.org/10.1097/01.ju.0000093721.23249.c3.

    Article  PubMed  Google Scholar 

  140. Kachnic LA, Shipley WU, Griffin PP, et al. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. Cancer J Sci Am. 1996;2(2):79–84.

    CAS  PubMed  Google Scholar 

  141. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(25):4055–61. https://doi.org/10.1200/JCO.2008.19.5776.

    Article  CAS  Google Scholar 

  142. Freilich JM, Spiess PE, Biagioli MC, et al. Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. Int Braz J Urol. 2014;40(2):190–7. https://doi.org/10.1590/S1677-5538.IBJU.2014.02.08.

    Article  PubMed  Google Scholar 

  143. Kibrom AZ, Knight KA. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci. 2015;62(4):277–85. https://doi.org/10.1002/jmrs.129.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–62. https://doi.org/10.1016/j.ijrobp.2011.05.051.

    Article  PubMed  Google Scholar 

  145. Foroudi F, Wilson L, Bressel M, et al. A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol. 2012;7:111. https://doi.org/10.1186/1748-717X-7-111.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

    Amishi Bajaj & Sean Sachdev

Authors
  1. Amishi Bajaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean Sachdev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean Sachdev .

Editor information

Editors and Affiliations

  1. Urology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

    Kelly L. Stratton

  2. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Alicia K. Morgans

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bajaj, A., Sachdev, S. (2022). Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer. In: Stratton, K.L., Morgans, A.K. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-89891-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-89891-5_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-89890-8

  • Online ISBN: 978-3-030-89891-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation